Brainsway (BWAY) Stock Price, News & Analysis

Company Overview

Brainsway (NASDAQ: BWAY) is an Israeli medical device company headquartered in Jerusalem that specializes in designing, developing and marketing non-invasive neurostimulation technologies for the treatment of psychiatric and neurological disorders. Founded in 2003, the company’s core mission is to provide safe, drug-free alternatives for patients who have shown inadequate response to conventional therapies.

The company’s flagship offering is the Deep Transcranial Magnetic Stimulation (Deep TMS) system, which utilizes patented H-coil technology to deliver magnetic pulses to specific brain regions. Deep TMS has received U.S. Food and Drug Administration clearances for treatment-resistant depression, obsessive-compulsive disorder and nicotine dependence. Beyond its approved indications, Brainsway is advancing a pipeline of coil configurations and treatment protocols targeting conditions such as anxiety, post-traumatic stress disorder and chronic pain.

Brainsway maintains a global footprint, with direct sales operations and distribution partnerships across North America, Europe, Asia-Pacific and Israel. The company collaborates with leading academic institutions and clinical centers to conduct pivotal trials and expand the scientific evidence supporting its therapies. A dedicated network of clinical trainers and technical service teams ensures healthcare providers receive comprehensive support for implementing and maintaining Deep TMS systems in hospitals, outpatient clinics and specialized treatment centers.

Since its initial public offering on the Nasdaq, Brainsway has steadily grown its installed base of Deep TMS systems while securing broader reimbursement coverage and forging strategic alliances. Under the leadership of Chief Executive Officer Ohad Tal and a management team with deep expertise in medical technology and neuroscience, Brainsway continues to invest in research and development. The company’s ongoing efforts focus on enhancing its existing product portfolio and exploring new applications for non-invasive brain stimulation in mental health and neurological care.

Key Stats

• Today's Range: $12.11 to $12.49
• 50-Day Range: $8.61 to $13.37
• 52-Week Range: $5.98 to $13.66
• Volume: 71,977 shs
• Average Volume: 67,960 shs
• Market Capitalization: $232.66 million
• P/E Ratio: 61.55
• Dividend Yield: N/A
• Price Target: $14.25
• Consensus Rating: Buy

Brainsway Stock Analysis - MarketRank™

Brainsway scored higher than 54% of companies evaluated by MarketBeat, and ranked 526th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Brainsway has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Brainsway has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 100.00%

Earnings Growth

Earnings for Brainsway are expected to grow by 100.00% in the coming year, from $0.08 to $0.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainsway is 61.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.30.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainsway is 61.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.28.

Price to Book Value per Share Ratio

Brainsway has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.81% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently decreased by 0.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainsway does not currently pay a dividend.

Dividend Growth

Brainsway does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.81% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently decreased by 0.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Brainsway has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Brainsway this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainsway insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.11% of the stock of Brainsway is held by institutions.

BWAY Stock Analysis - Frequently Asked Questions

How have BWAY shares performed this year?

Brainsway's stock was trading at $9.43 at the beginning of 2025. Since then, BWAY shares have increased by 30.5% and is now trading at $12.31.

How were Brainsway's earnings last quarter?

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) released its earnings results on Tuesday, May, 13th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The business had revenue of $11.54 million for the quarter, compared to the consensus estimate of $11.45 million. Brainsway had a net margin of 9.01% and a trailing twelve-month return on equity of 7.35%.
Read the conference call transcript.

When did Brainsway IPO?

Brainsway (BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO.

How do I buy shares of Brainsway?

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brainsway own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainsway investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BWAY
• CIK: 1505065
• Web: www.brainsway.com
• Phone: (722) 582-4030
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Brainsway: $14.25
• High Price Target: $16.00
• Low Price Target: $12.50
• Potential Upside/Downside: +15.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.20
• Trailing P/E Ratio: 61.55
• Forward P/E Ratio: 153.88
• P/E Growth: N/A
• Net Income: $2.92 million
• Net Margins: 9.01%
• Pretax Margin: 10.22%
• Return on Equity: 7.35%
• Return on Assets: 4.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.03
• Quick Ratio: 4.75

Sales & Book Value

• Annual Sales: $41.02 million
• Price / Sales: 5.67
• Cash Flow: $0.25 per share
• Price / Cash Flow: 49.37
• Book Value: $3.31 per share
• Price / Book: 3.72

Miscellaneous

• Outstanding Shares: 18,900,000
• Free Float: 15,307,000
• Market Cap: $232.66 million
• Optionable: Not Optionable
• Beta: 1.40